Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2511912,oral clearance,The oral clearance of R-flecainide (467 +/- 109 ml min-1) was less (P less than 0.03) than that of the S-enantiomer (620 +/- 172 ml min-1).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),[ml] / [min],467,14691,DB01195,Flecainide
,2511912,oral clearance,The oral clearance of R-flecainide (467 +/- 109 ml min-1) was less (P less than 0.03) than that of the S-enantiomer (620 +/- 172 ml min-1).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),[ml] / [min],620,14692,DB01195,Flecainide
,2511912,half-life,The half-life of R-flecainide (12.9 h) was longer (P less than 0.03) than that of S-flecainide (9.8 h).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),h,12.9,14693,DB01195,Flecainide
,2511912,half-life,The half-life of R-flecainide (12.9 h) was longer (P less than 0.03) than that of S-flecainide (9.8 h).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),h,9.8,14694,DB01195,Flecainide
,2511912,urinary recovery,The urinary recovery of R-flecainide (15.6 +/- 3.7 mg) was greater (P less than 0.03) than that of the S-enantiomer (12.0 +/- 3.7 mg).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),mg,15.6,14695,DB01195,Flecainide
,2511912,urinary recovery,The urinary recovery of R-flecainide (15.6 +/- 3.7 mg) was greater (P less than 0.03) than that of the S-enantiomer (12.0 +/- 3.7 mg).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),mg,12.0,14696,DB01195,Flecainide
,2511912,urinary recoveries,"4. The urinary recoveries of two major metabolites of flecainide, meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) were lower (P less than 0.05) in PMs, 12.0% +/- 3.1% and 8.2% +/- 3.2% of the dose administered, respectively, than in EMs of 17.7% +/- 3.3% and 16.5% +/- 3.3%, respectively.",Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),%,12.0,14697,DB01195,Flecainide
,2511912,urinary recoveries,"4. The urinary recoveries of two major metabolites of flecainide, meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) were lower (P less than 0.05) in PMs, 12.0% +/- 3.1% and 8.2% +/- 3.2% of the dose administered, respectively, than in EMs of 17.7% +/- 3.3% and 16.5% +/- 3.3%, respectively.",Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),%,8.2,14698,DB01195,Flecainide
,2511912,urinary recoveries,"4. The urinary recoveries of two major metabolites of flecainide, meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) were lower (P less than 0.05) in PMs, 12.0% +/- 3.1% and 8.2% +/- 3.2% of the dose administered, respectively, than in EMs of 17.7% +/- 3.3% and 16.5% +/- 3.3%, respectively.",Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),%,17.7,14699,DB01195,Flecainide
,2511912,urinary recoveries,"4. The urinary recoveries of two major metabolites of flecainide, meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) were lower (P less than 0.05) in PMs, 12.0% +/- 3.1% and 8.2% +/- 3.2% of the dose administered, respectively, than in EMs of 17.7% +/- 3.3% and 16.5% +/- 3.3%, respectively.",Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),%,16.5,14700,DB01195,Flecainide
,32249350,concentrations,"The predicted flecainide concentrations after multiple flecainide doses (50 mg BID) in the anuric hemodialysis with cirrhosis population were comparable with the observed value (3602 ng/mL), which fell between the predicted concentrations in the absence and presence of mexiletine (3043 [718-8499] and 5914 [880-20,624] ng/mL, respectively).",Utilizing physiologically based pharmacokinetic modeling to predict theoretically conceivable extreme elevation of serum flecainide concentration in an anuric hemodialysis patient with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32249350/),[ng] / [ml],3043,16636,DB01195,Flecainide
,32249350,concentrations,"The predicted flecainide concentrations after multiple flecainide doses (50 mg BID) in the anuric hemodialysis with cirrhosis population were comparable with the observed value (3602 ng/mL), which fell between the predicted concentrations in the absence and presence of mexiletine (3043 [718-8499] and 5914 [880-20,624] ng/mL, respectively).",Utilizing physiologically based pharmacokinetic modeling to predict theoretically conceivable extreme elevation of serum flecainide concentration in an anuric hemodialysis patient with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32249350/),[ng] / [ml],5914,16637,DB01195,Flecainide
,6364769,plasma half-life,"In healthy subjects, the plasma half-life of unchanged flecainide is relatively long (mean 13 hours after single doses and 16 hours after multiple dosage).",Metabolism of flecainide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364769/),h,13,26888,DB01195,Flecainide
,6364769,plasma half-life,"In healthy subjects, the plasma half-life of unchanged flecainide is relatively long (mean 13 hours after single doses and 16 hours after multiple dosage).",Metabolism of flecainide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364769/),h,16,26889,DB01195,Flecainide
,6364769,half-life,"For patients with ventricular premature complexes, the half-life is longer (mean 20 hours), and twice-daily oral dosage is effective.",Metabolism of flecainide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6364769/),h,20,26890,DB01195,Flecainide
,3104059,elimination half-time,"The elimination half-time in the patients with impaired renal function was significantly longer (19.9, SD 9.9 h) than that in the patients with normal renal function (11.5, SD 4.2 h), but the variability in the elimination half-time in renal failure could not be explained on the basis of the available results.",Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104059/),h,19.9,36488,DB01195,Flecainide
,3104059,elimination half-time,"The elimination half-time in the patients with impaired renal function was significantly longer (19.9, SD 9.9 h) than that in the patients with normal renal function (11.5, SD 4.2 h), but the variability in the elimination half-time in renal failure could not be explained on the basis of the available results.",Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3104059/),h,11.5,36489,DB01195,Flecainide
,8268824,recoveries,"Mean recoveries of 70 and 63% were obtained for verapamil and flecainide, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),%,70,36985,DB01195,Flecainide
,8268824,recoveries,"Mean recoveries of 70 and 63% were obtained for verapamil and flecainide, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),%,63,36986,DB01195,Flecainide
,8268824,area under the curve from 0 to 24 h (AUC[0-24]),"The mean values for the area under the curve from 0 to 24 h (AUC[0-24]), maximum achieved concentration (Cmax) and time to achieve the maximum concentration (Tmax) were 863 ng h-1 ml-1, 112 ng/ml and 4 h, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),[ng] / [h·ml],863,36987,DB01195,Flecainide
,8268824,maximum achieved concentration (Cmax),"The mean values for the area under the curve from 0 to 24 h (AUC[0-24]), maximum achieved concentration (Cmax) and time to achieve the maximum concentration (Tmax) were 863 ng h-1 ml-1, 112 ng/ml and 4 h, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),[ng] / [ml],112,36988,DB01195,Flecainide
,8268824,time to achieve the maximum concentration (Tmax),"The mean values for the area under the curve from 0 to 24 h (AUC[0-24]), maximum achieved concentration (Cmax) and time to achieve the maximum concentration (Tmax) were 863 ng h-1 ml-1, 112 ng/ml and 4 h, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),h,4,36989,DB01195,Flecainide
,24523024,flow rate,"The mobile phase solution, comprising 0.1 m potassium hexafluorophosphate and acetonitrile (65:35, v/v), was pumped at a flow rate of 0.5 mL/min.",Stereoselective analysis of flecainide enantiomers using reversed-phase liquid chromatography for assessing CYP2D6 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24523024/),[ml] / [min],0.5,37623,DB01195,Flecainide
,24523024,S/R ratio,The S/R ratio of trough serum flecainide concentration ranged from 0.79 to 1.16 in patients receiving oral flecainide.,Stereoselective analysis of flecainide enantiomers using reversed-phase liquid chromatography for assessing CYP2D6 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24523024/),,0.79 to 1.16,37624,DB01195,Flecainide
,2504263,terminal half life,"Pharmacokinetic variables were calculated--median terminal half life 7.5 hours, median volume of distribution 6.2 l/kg, and median plasma clearance 7.2 ml/min/kg.",Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504263/),h,7.5,50385,DB01195,Flecainide
,2504263,volume of distribution,"Pharmacokinetic variables were calculated--median terminal half life 7.5 hours, median volume of distribution 6.2 l/kg, and median plasma clearance 7.2 ml/min/kg.",Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504263/),[l] / [kg],6.2,50386,DB01195,Flecainide
,2504263,plasma clearance,"Pharmacokinetic variables were calculated--median terminal half life 7.5 hours, median volume of distribution 6.2 l/kg, and median plasma clearance 7.2 ml/min/kg.",Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504263/),[ml] / [kg·min],7.2,50387,DB01195,Flecainide
,2504263,time to maximum concentration,"Pharmacokinetic variables were calculated: time to maximum concentration 2 hours, median terminal half life 7.9 hours.",Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504263/),h,2,50388,DB01195,Flecainide
,2504263,terminal half life,"Pharmacokinetic variables were calculated: time to maximum concentration 2 hours, median terminal half life 7.9 hours.",Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2504263/),h,7.9,50389,DB01195,Flecainide
,3094042,final half lives,"The final half lives in plasma and tissues were about 4 hours, except in the brain where the half life value was 9.8 hours.",Plasma and tissue levels of flecainide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094042/),h,4,53697,DB01195,Flecainide
,3094042,half life,"The final half lives in plasma and tissues were about 4 hours, except in the brain where the half life value was 9.8 hours.",Plasma and tissue levels of flecainide in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094042/),h,9.8,53698,DB01195,Flecainide
,3094042,tissue/plasma (T/P) ratios,"The mean tissue/plasma (T/P) ratios in myocardial, kidney, liver, skeletal and muscle tissues were 9.11, 13.8, 14.37, 6.31 respectively, while in the brain the T/P ratio rose progressively over the sampling time to 10.0.",Plasma and tissue levels of flecainide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094042/),,9.11,53699,DB01195,Flecainide
,3094042,tissue/plasma (T/P) ratios,"The mean tissue/plasma (T/P) ratios in myocardial, kidney, liver, skeletal and muscle tissues were 9.11, 13.8, 14.37, 6.31 respectively, while in the brain the T/P ratio rose progressively over the sampling time to 10.0.",Plasma and tissue levels of flecainide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094042/),,13.8,53700,DB01195,Flecainide
,3094042,tissue/plasma (T/P) ratios,"The mean tissue/plasma (T/P) ratios in myocardial, kidney, liver, skeletal and muscle tissues were 9.11, 13.8, 14.37, 6.31 respectively, while in the brain the T/P ratio rose progressively over the sampling time to 10.0.",Plasma and tissue levels of flecainide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094042/),,14.37,53701,DB01195,Flecainide
,3094042,tissue/plasma (T/P) ratios,"The mean tissue/plasma (T/P) ratios in myocardial, kidney, liver, skeletal and muscle tissues were 9.11, 13.8, 14.37, 6.31 respectively, while in the brain the T/P ratio rose progressively over the sampling time to 10.0.",Plasma and tissue levels of flecainide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094042/),,6.31,53702,DB01195,Flecainide
,3094042,T/P ratio,"The mean tissue/plasma (T/P) ratios in myocardial, kidney, liver, skeletal and muscle tissues were 9.11, 13.8, 14.37, 6.31 respectively, while in the brain the T/P ratio rose progressively over the sampling time to 10.0.",Plasma and tissue levels of flecainide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094042/),,10.0,53703,DB01195,Flecainide
,3741720,tmax,Six days pretreatment with cimetidine induced the following changes in flecainide kinetic parameters: average tmax was prolonged from 1.8 h to 3.6 h and total AUC increased significantly from 4779 to 6131 ng ml-1 h.,Altered pharmacokinetics of oral flecainide by cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741720/),h,1.8,53955,DB01195,Flecainide
,3741720,tmax,Six days pretreatment with cimetidine induced the following changes in flecainide kinetic parameters: average tmax was prolonged from 1.8 h to 3.6 h and total AUC increased significantly from 4779 to 6131 ng ml-1 h.,Altered pharmacokinetics of oral flecainide by cimetidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741720/),h,3.6,53956,DB01195,Flecainide
,3741720,total AUC,Six days pretreatment with cimetidine induced the following changes in flecainide kinetic parameters: average tmax was prolonged from 1.8 h to 3.6 h and total AUC increased significantly from 4779 to 6131 ng ml-1 h.,Altered pharmacokinetics of oral flecainide by cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741720/),[h·ng] / [ml],4779,53957,DB01195,Flecainide
,3741720,total AUC,Six days pretreatment with cimetidine induced the following changes in flecainide kinetic parameters: average tmax was prolonged from 1.8 h to 3.6 h and total AUC increased significantly from 4779 to 6131 ng ml-1 h.,Altered pharmacokinetics of oral flecainide by cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741720/),[h·ng] / [ml],6131,53958,DB01195,Flecainide
,2501057,plasma clearance,"Verapamil slightly decreased the plasma clearance of flecainide (7.78 +/- 0.60 ml/kg/min for flecainide alone, 7.34 +/- 0.48 ml/kg/min for flecainide and verapamil together, p less than 0.05).",The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501057/),[ml] / [kg·min],7.78,59211,DB01195,Flecainide
,2501057,plasma clearance,"Verapamil slightly decreased the plasma clearance of flecainide (7.78 +/- 0.60 ml/kg/min for flecainide alone, 7.34 +/- 0.48 ml/kg/min for flecainide and verapamil together, p less than 0.05).",The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501057/),[ml] / [kg·min],7.34,59212,DB01195,Flecainide
,7621848,metabolic clearances,Six subjects with a wide range of flecainide metabolic clearances (85-407 ml.min-1) simultaneously received the drug by the IV and oral routes; the oral dose was labelled with deuterium.,Estimation of the absolute bioavailability of flecainide using stable isotope technique. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621848/),[ml] / [min],85-407,71914,DB01195,Flecainide
,7621848,absolute bioavailability,The absolute bioavailability of flecainide ranged from 79.9 to 101.1% (mean 93.6%).,Estimation of the absolute bioavailability of flecainide using stable isotope technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621848/),%,93.6,71915,DB01195,Flecainide
,7621848,absorption,The absorption was 86.1 to 101.3% (mean 93.2%).,Estimation of the absolute bioavailability of flecainide using stable isotope technique. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621848/),%,86.1 to 101.3,71916,DB01195,Flecainide
,7621848,absorption,The absorption was 86.1 to 101.3% (mean 93.2%).,Estimation of the absolute bioavailability of flecainide using stable isotope technique. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7621848/),%,93.2,71917,DB01195,Flecainide
,16132275,volume of distribution at steady state,The mean maternal volume of distribution at steady state was 5.1 +/- 1.8 L/kg.,Transplacental pharmacokinetics of flecainide in the gravid baboon and fetus. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132275/),[l] / [kg],5.1,72931,DB01195,Flecainide
,16132275,combined elimination constant (k(el)),"The mean combined elimination constant (k(el)) was 0.79 +/- 0.19 hr(-1) [95% confidence interval (CI), 0.64-0.93].",Transplacental pharmacokinetics of flecainide in the gravid baboon and fetus. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132275/),1/[hr],0.79,72932,DB01195,Flecainide
,1451729,volume of distribution,"Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[l] / [kg],7.9,79617,DB01195,Flecainide
,1451729,volume of distribution,"Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[l] / [kg],7.4,79618,DB01195,Flecainide
,1451729,half-life,"Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),h,8.8,79619,DB01195,Flecainide
,1451729,half-life,"Quinidine (50 mg orally), given the previous evening, did not change the volume of distribution of flecainide (7.9 vs 7.4 l.kg-1), but significantly increased its half-life (8.8 vs 10.7 h).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),h,10.7,79620,DB01195,Flecainide
,1451729,total clearance,"This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kg·min],10.6,79621,DB01195,Flecainide
,1451729,total clearance,"This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kg·min],8.1,79622,DB01195,Flecainide
,1451729,non-renal clearance,"This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kg·min],7.2,79623,DB01195,Flecainide
,1451729,non-renal clearance,"This was attributable to a reduction in total clearance (10.6 vs 8.1 ml.min-1 x kg-1), most of it being accounted for by a reduction in non-renal clearance (7.2 vs 5.2 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kg·min],5.2,79624,DB01195,Flecainide
,1451729,renal clearance,"These findings suggest that quinidine inhibits the first step of flecainide metabolism, although it may also reduce its renal clearance, but to a lesser extent (3.5 vs 2.9 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kg·min],3.5,79625,DB01195,Flecainide
,1451729,renal clearance,"These findings suggest that quinidine inhibits the first step of flecainide metabolism, although it may also reduce its renal clearance, but to a lesser extent (3.5 vs 2.9 ml.min-1 x kg-1).",The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1451729/),[ml] / [kg·min],2.9,79626,DB01195,Flecainide
,9140253,half-life,"During 10 hours of CBS, the flecainide level decreased to 1.4 micrograms/mL, a half-life of 6 hours.",Flecainide overdose: is cardiopulmonary support the treatment? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9140253/),h,6,84065,DB01195,Flecainide
,2503250,minimum concentrations,"Since short PR and delta wave are the expression of pre-excitation, we were able to determine the minimum concentrations capable to inhibit conduction through the abnormal bundles (290.0 ng ml-1 in the acutely treated patient and average 275.0 ng ml-1 in the chronically treated patients).",[Pharmacodynamics and pharmacokinetics of flecainide in cardiac pre-excitation of the bundle of Kent]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503250/),[ng] / [ml],290.0,88174,DB01195,Flecainide
,2503250,minimum concentrations,"Since short PR and delta wave are the expression of pre-excitation, we were able to determine the minimum concentrations capable to inhibit conduction through the abnormal bundles (290.0 ng ml-1 in the acutely treated patient and average 275.0 ng ml-1 in the chronically treated patients).",[Pharmacodynamics and pharmacokinetics of flecainide in cardiac pre-excitation of the bundle of Kent]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2503250/),[ng] / [ml],275.0,88175,DB01195,Flecainide
,15619132,maximum concentration (C (max\ fit)),The tablets gave a maximum concentration (C (max\ fit)) of 0.43+/-0.14 mg/l at 2.37+/-1.20 h.,Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619132/),[mg] / [l],0.43,90485,DB01195,Flecainide
,15619132,C (max\ fit),"The C (max\ fit) of the oral solution of 0.60+/-0.17 mg/l was higher (P=0.0002) than that of the tablets, and interindividual variabilities of C (max\ fit) were 28% and 33%, respectively.",Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619132/),[mg] / [l],0.60,90486,DB01195,Flecainide
,3141098,t1/2,The mean plasma antipyrine t1/2 for patients (42.2 hours) was longer (p less than 0.01) than that for subjects (11.7 hours).,Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),h,42.2,93183,DB01195,Flecainide
,3141098,t1/2,The mean plasma antipyrine t1/2 for patients (42.2 hours) was longer (p less than 0.01) than that for subjects (11.7 hours).,Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),h,11.7,93184,DB01195,Flecainide
,3141098,plasma t1/2,"For control subjects, the plasma t1/2 of flecainide (9.5 hours) was shorter (p less than 0.01), plasma clearance (9.1 ml/min/kg) was faster (p less than 0.01), and volume of distribution (7.5 L/kg) was smaller (p less than 0.05) compared with corresponding values in patients.",Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),h,9.5,93185,DB01195,Flecainide
,3141098,plasma clearance,"For control subjects, the plasma t1/2 of flecainide (9.5 hours) was shorter (p less than 0.01), plasma clearance (9.1 ml/min/kg) was faster (p less than 0.01), and volume of distribution (7.5 L/kg) was smaller (p less than 0.05) compared with corresponding values in patients.",Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),[ml] / [kg·min],9.1,93186,DB01195,Flecainide
,3141098,volume of distribution,"For control subjects, the plasma t1/2 of flecainide (9.5 hours) was shorter (p less than 0.01), plasma clearance (9.1 ml/min/kg) was faster (p less than 0.01), and volume of distribution (7.5 L/kg) was smaller (p less than 0.05) compared with corresponding values in patients.",Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141098/),[l] / [kg],7.5,93187,DB01195,Flecainide
,11411495,maximum plasma concentration,"The maximum plasma concentration reached 1014+/-285 (SD) ng/m/ in 45+/-13 min and 1301+/-400 ng/ m/l in 60+/-37 min for doses of 4 and 6 mg/kg flecainide, respectively.",Determination of oral dosage and pharmacokinetic analysis of flecainide in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11411495/),[ng] / [m],1014,107829,DB01195,Flecainide
,11411495,maximum plasma concentration,"The maximum plasma concentration reached 1014+/-285 (SD) ng/m/ in 45+/-13 min and 1301+/-400 ng/ m/l in 60+/-37 min for doses of 4 and 6 mg/kg flecainide, respectively.",Determination of oral dosage and pharmacokinetic analysis of flecainide in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11411495/),[ng] / [l·m],1301,107830,DB01195,Flecainide
,11411495,clearance rates,"From the pharmacokinetic analysis, clearance rates were 14.6+/-6.4 and 11.7+/-5.2 ml/kg/min and terminal elimination half-lives were 228+/-53 and 304+/-87 min.",Determination of oral dosage and pharmacokinetic analysis of flecainide in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11411495/),[ml] / [kg·min],14.6,107831,DB01195,Flecainide
,11411495,clearance rates,"From the pharmacokinetic analysis, clearance rates were 14.6+/-6.4 and 11.7+/-5.2 ml/kg/min and terminal elimination half-lives were 228+/-53 and 304+/-87 min.",Determination of oral dosage and pharmacokinetic analysis of flecainide in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11411495/),[ml] / [kg·min],11.7,107832,DB01195,Flecainide
,11411495,terminal elimination half-lives,"From the pharmacokinetic analysis, clearance rates were 14.6+/-6.4 and 11.7+/-5.2 ml/kg/min and terminal elimination half-lives were 228+/-53 and 304+/-87 min.",Determination of oral dosage and pharmacokinetic analysis of flecainide in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11411495/),min,228,107833,DB01195,Flecainide
,11411495,terminal elimination half-lives,"From the pharmacokinetic analysis, clearance rates were 14.6+/-6.4 and 11.7+/-5.2 ml/kg/min and terminal elimination half-lives were 228+/-53 and 304+/-87 min.",Determination of oral dosage and pharmacokinetic analysis of flecainide in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11411495/),min,304,107834,DB01195,Flecainide
,17665182,nonrenal clearance,"We confirmed that nonrenal clearance of flecainide among healthy subjects was significantly higher in males than in females (0.77 +/- 0.16 versus 0.57 +/- 0.06 L h(-1) kg(-1), P < 0.05).",Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17665182/),[l] / [h·kg],0.77,115603,DB01195,Flecainide
,17665182,nonrenal clearance,"We confirmed that nonrenal clearance of flecainide among healthy subjects was significantly higher in males than in females (0.77 +/- 0.16 versus 0.57 +/- 0.06 L h(-1) kg(-1), P < 0.05).",Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17665182/),[l] / [h·kg],0.57,115604,DB01195,Flecainide
,3129880,concentrations,"Just prior to the first morning dose, amiodarone concentrations in plasma were 1.0-2.9 (2.0 +/- 0.6) micrograms/ml, in saliva 0.02-0.25 micrograms/ml; flecainide in plasma 80-560 (316 +/- 163) ng/ml, in saliva 630-3700 (1749 +/- 963) ng/ml.",[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],316,121796,DB01195,Flecainide
,3129880,concentrations,"Just prior to the first morning dose, amiodarone concentrations in plasma were 1.0-2.9 (2.0 +/- 0.6) micrograms/ml, in saliva 0.02-0.25 micrograms/ml; flecainide in plasma 80-560 (316 +/- 163) ng/ml, in saliva 630-3700 (1749 +/- 963) ng/ml.",[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],1749,121797,DB01195,Flecainide
,3129880,maximal flecainide,After the morning dose we found maximal flecainide plasma levels of 462 +/- 203 and saliva levels of 3218 +/- 2857 ng/ml.,[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],462,121798,DB01195,Flecainide
,3129880,plasma levels,After the morning dose we found maximal flecainide plasma levels of 462 +/- 203 and saliva levels of 3218 +/- 2857 ng/ml.,[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],462,121799,DB01195,Flecainide
,3129880,plasma levels,After the morning dose we found maximal flecainide plasma levels of 462 +/- 203 and saliva levels of 3218 +/- 2857 ng/ml.,[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],3218,121800,DB01195,Flecainide
,3129880,saliva,After the morning dose we found maximal flecainide plasma levels of 462 +/- 203 and saliva levels of 3218 +/- 2857 ng/ml.,[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],3218,121801,DB01195,Flecainide
,3129880,concentrations,"The highest flecainide concentrations in the saliva (13,400 and 11,300 ng/ml) were found in two patients 30 and 60 min after the morning dose.",[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],"13,400",121802,DB01195,Flecainide
,3129880,concentrations,"The highest flecainide concentrations in the saliva (13,400 and 11,300 ng/ml) were found in two patients 30 and 60 min after the morning dose.",[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129880/),[ng] / [ml],"11,300",121803,DB01195,Flecainide
,16944116,CL/F,"Using a Bayesian method we estimated that the CL/F in IMs was significantly lower than in homozygous EMs (0.25+/-0.05 l h(-1) kg(-1) vs. 0.37+/-0.08 l h(-1) kg(-1), P<0.05) among male patients under 70 years old.",Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16944116/),[l] / [h·kg],0.25,121988,DB01195,Flecainide
,16944116,CL/F,"Using a Bayesian method we estimated that the CL/F in IMs was significantly lower than in homozygous EMs (0.25+/-0.05 l h(-1) kg(-1) vs. 0.37+/-0.08 l h(-1) kg(-1), P<0.05) among male patients under 70 years old.",Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16944116/),[l] / [h·kg],0.37,121989,DB01195,Flecainide
,29923887,peak venous plasma levels,"Intratracheal instillation of flecainide (0.75 and 1.5 mg/kg, rapid bolus) caused dose/concentration-dependent increases in the QRS complex duration of 10% and 19%, respectively, at 2 minutes, coinciding with peak venous plasma levels (1688 ± 177 and 2808 ± 217 ng/mL, respectively).",Comparative Pharmacokinetic and Electrocardiographic Effects of Intratracheal and Intravenous Administration of Flecainide in Anesthetized Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923887/),[ng] / [ml],1688,123182,DB01195,Flecainide
,29923887,peak venous plasma levels,"Intratracheal instillation of flecainide (0.75 and 1.5 mg/kg, rapid bolus) caused dose/concentration-dependent increases in the QRS complex duration of 10% and 19%, respectively, at 2 minutes, coinciding with peak venous plasma levels (1688 ± 177 and 2808 ± 217 ng/mL, respectively).",Comparative Pharmacokinetic and Electrocardiographic Effects of Intratracheal and Intravenous Administration of Flecainide in Anesthetized Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923887/),[ng] / [ml],2808,123183,DB01195,Flecainide
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124537,DB01195,Flecainide
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,24,124538,DB01195,Flecainide
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,34,124539,DB01195,Flecainide
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,27,124540,DB01195,Flecainide
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124541,DB01195,Flecainide
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,37,124542,DB01195,Flecainide
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),m,562,133193,DB01195,Flecainide
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[ng] / [ml],342,133194,DB01195,Flecainide
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[ng] / [ml],270,133195,DB01195,Flecainide
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[ng] / [ml],240,133196,DB01195,Flecainide
,2507556,plasma concentration,"Mean FLC plasma concentration values at 0, 1, 2, 4, and 8 h following administration were 562 +/- 271, 342 +/- 129, 270 +/- 90m, 240 +/- 80 and 210 +/- 60 ng/ml, respectively.",Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[ng] / [ml],210,133197,DB01195,Flecainide
,2507556,terminal plasma half-life (t1/2 beta),Mean values for the terminal plasma half-life (t1/2 beta) was 22.0 +/- 9.7 h and the volume of distribution (V beta) was 7.99 +/- 3.02 1/kg.,Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),h,22.0,133198,DB01195,Flecainide
,2507556,volume of distribution (V beta),Mean values for the terminal plasma half-life (t1/2 beta) was 22.0 +/- 9.7 h and the volume of distribution (V beta) was 7.99 +/- 3.02 1/kg.,Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2507556/),[1] / [kg],7.99,133199,DB01195,Flecainide
,3146507,t1/2abs,Rectal absorption was found to be fast (t1/2abs = 1 h) and complete when flecainide was administered as a solution (relative bioavailability 100%).,Rectal absorption of flecainide acetate. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146507/),h,1,139290,DB01195,Flecainide
,3146507,relative bioavailability,Rectal absorption was found to be fast (t1/2abs = 1 h) and complete when flecainide was administered as a solution (relative bioavailability 100%).,Rectal absorption of flecainide acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146507/),%,100,139291,DB01195,Flecainide
,3146507,relative bioavailability,The polyethyleneglycol suppository gave absorption with a relative bioavailability of 80% and t1/2 abs = 1.2 h.,Rectal absorption of flecainide acetate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146507/),%,80,139292,DB01195,Flecainide
,3146507,t1/2 abs,The polyethyleneglycol suppository gave absorption with a relative bioavailability of 80% and t1/2 abs = 1.2 h.,Rectal absorption of flecainide acetate. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3146507/),h,1.2,139293,DB01195,Flecainide
,2115446,absolute bioavailability,"The mean absolute bioavailability was 98%, 78% and 81% for the rectal and oral solutions and the tablet.",Absorption kinetics of oral and rectal flecainide in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),%,98,140709,DB01195,Flecainide
,2115446,absolute bioavailability,"The mean absolute bioavailability was 98%, 78% and 81% for the rectal and oral solutions and the tablet.",Absorption kinetics of oral and rectal flecainide in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),%,78,140710,DB01195,Flecainide
,2115446,absolute bioavailability,"The mean absolute bioavailability was 98%, 78% and 81% for the rectal and oral solutions and the tablet.",Absorption kinetics of oral and rectal flecainide in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),%,81,140711,DB01195,Flecainide
,2115446,lag time,The lag time after administration of the oral solution was 0.33 h and it was 0.86 h after the tablet and 0.18 h after the rectal solution.,Absorption kinetics of oral and rectal flecainide in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),h,0.33,140712,DB01195,Flecainide
,2115446,lag time,The lag time after administration of the oral solution was 0.33 h and it was 0.86 h after the tablet and 0.18 h after the rectal solution.,Absorption kinetics of oral and rectal flecainide in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),h,0.86,140713,DB01195,Flecainide
,2115446,lag time,The lag time after administration of the oral solution was 0.33 h and it was 0.86 h after the tablet and 0.18 h after the rectal solution.,Absorption kinetics of oral and rectal flecainide in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),h,0.18,140714,DB01195,Flecainide
,2115446,time to the peak serum concentration (tmax),The mean time to the peak serum concentration (tmax) after the rectal solution (0.67 h) was shorter than after either the tablet (4 h) or oral solution (1 h).,Absorption kinetics of oral and rectal flecainide in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),h,0.67,140715,DB01195,Flecainide
,2115446,time to the peak serum concentration (tmax),The mean time to the peak serum concentration (tmax) after the rectal solution (0.67 h) was shorter than after either the tablet (4 h) or oral solution (1 h).,Absorption kinetics of oral and rectal flecainide in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),h,4,140716,DB01195,Flecainide
,2115446,time to the peak serum concentration (tmax),The mean time to the peak serum concentration (tmax) after the rectal solution (0.67 h) was shorter than after either the tablet (4 h) or oral solution (1 h).,Absorption kinetics of oral and rectal flecainide in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),h,1,140717,DB01195,Flecainide
,2115446,maximum serum concentration (Cmax),"The maximum serum concentration (Cmax) was 0.29 mg.l-1 after the rectal solution, 0.14 mg.l-1 after the tablet and 0.17 mg.l-1 after the oral solution.",Absorption kinetics of oral and rectal flecainide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),[mg] / [l],0.29,140718,DB01195,Flecainide
,2115446,maximum serum concentration (Cmax),"The maximum serum concentration (Cmax) was 0.29 mg.l-1 after the rectal solution, 0.14 mg.l-1 after the tablet and 0.17 mg.l-1 after the oral solution.",Absorption kinetics of oral and rectal flecainide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),[mg] / [l],0.14,140719,DB01195,Flecainide
,2115446,maximum serum concentration (Cmax),"The maximum serum concentration (Cmax) was 0.29 mg.l-1 after the rectal solution, 0.14 mg.l-1 after the tablet and 0.17 mg.l-1 after the oral solution.",Absorption kinetics of oral and rectal flecainide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2115446/),[mg] / [l],0.17,140720,DB01195,Flecainide
,6148206,cumulative recovery of radioactivity,"The cumulative recovery of radioactivity ranged from 81 to 90% (mean, 86%) in urine and from 4 to 6% (mean, 5%) in feces; thus, flecainide does not appear to undergo extensive biliary excretion, unless reabsorption occurs after biliary elimination.",Biotransformation and elimination of 14C-flecainide acetate in humans. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148206/),%,81 to 90,140980,DB01195,Flecainide
,6148206,cumulative recovery of radioactivity,"The cumulative recovery of radioactivity ranged from 81 to 90% (mean, 86%) in urine and from 4 to 6% (mean, 5%) in feces; thus, flecainide does not appear to undergo extensive biliary excretion, unless reabsorption occurs after biliary elimination.",Biotransformation and elimination of 14C-flecainide acetate in humans. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148206/),%,86,140981,DB01195,Flecainide
,6148206,cumulative recovery of radioactivity,"The cumulative recovery of radioactivity ranged from 81 to 90% (mean, 86%) in urine and from 4 to 6% (mean, 5%) in feces; thus, flecainide does not appear to undergo extensive biliary excretion, unless reabsorption occurs after biliary elimination.",Biotransformation and elimination of 14C-flecainide acetate in humans. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148206/),%,4 to 6,140982,DB01195,Flecainide
,6148206,cumulative recovery of radioactivity,"The cumulative recovery of radioactivity ranged from 81 to 90% (mean, 86%) in urine and from 4 to 6% (mean, 5%) in feces; thus, flecainide does not appear to undergo extensive biliary excretion, unless reabsorption occurs after biliary elimination.",Biotransformation and elimination of 14C-flecainide acetate in humans. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148206/),%,5,140983,DB01195,Flecainide
,6148206,cumulative excretion,"The cumulative excretion in urine of unchanged flecainide ranged from 35 to 50% (mean, 42%) of the dose and was essentially complete by 72 hr postdose.",Biotransformation and elimination of 14C-flecainide acetate in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148206/),%,35 to 50,140984,DB01195,Flecainide
,6148206,cumulative excretion,"The cumulative excretion in urine of unchanged flecainide ranged from 35 to 50% (mean, 42%) of the dose and was essentially complete by 72 hr postdose.",Biotransformation and elimination of 14C-flecainide acetate in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148206/),%,42,140985,DB01195,Flecainide
,6148206,Peak plasma levels,Peak plasma levels of radioactivity (524 to 848 ng eq/ml) and of unchanged flecainide (214 to 281 ng/ml) were attained at 2 to 3 hr postdose.,Biotransformation and elimination of 14C-flecainide acetate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148206/),[eq·ng] / [ml],524 to 848,140986,DB01195,Flecainide
,6148206,Peak plasma levels,Peak plasma levels of radioactivity (524 to 848 ng eq/ml) and of unchanged flecainide (214 to 281 ng/ml) were attained at 2 to 3 hr postdose.,Biotransformation and elimination of 14C-flecainide acetate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148206/),[ng] / [ml],214 to 281,140987,DB01195,Flecainide
,6148206,half-life,The average half-life for the disappearance of unchanged flecainide from plasma was about 16 hr; disappearance of total metabolites from plasma was only slightly slower.,Biotransformation and elimination of 14C-flecainide acetate in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148206/),h,16,140988,DB01195,Flecainide
,2107645,maximum flecainide plasma level,The maximum flecainide plasma level was 4900 ng/ml; this level is extremely high and exceeds the maximum therapeutic level by five times.,[Successful treatment of flecainide (Tambocor) poisoning--effect of hemodialysis/hemoperfusion?]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107645/),[ng] / [ml],4900,143640,DB01195,Flecainide
,2107645,plasma halflife,The initial decrease in flecainide plasma levels during extracorporeal elimination occurred much quicker (4.5-8.5 h plasma halflife) than the spontaneous decrease rate of flecainide in humans (12-20 h plasma half-life).,[Successful treatment of flecainide (Tambocor) poisoning--effect of hemodialysis/hemoperfusion?]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107645/),h,4.5-8.5,143641,DB01195,Flecainide
,2107645,plasma half-life,The initial decrease in flecainide plasma levels during extracorporeal elimination occurred much quicker (4.5-8.5 h plasma halflife) than the spontaneous decrease rate of flecainide in humans (12-20 h plasma half-life).,[Successful treatment of flecainide (Tambocor) poisoning--effect of hemodialysis/hemoperfusion?]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2107645/),h,12-20,143642,DB01195,Flecainide
exceeded,2514579,extraction recoveries,"The extraction recoveries exceeded 94%, and the coefficients of variation (both within the same day and in different days) were less than 5%.",[Determination of flecainide concentration in blood plasma by HPLC and pharmacokinetic parameters in volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514579/),%,94,145931,DB01195,Flecainide
,2514579,Ka,"The pharmacokinetic parameters in Chinese volunteers after taking flecainide were: Ka = 0.908h-1, T1/2 = 8.131h, peats time = 3.487h, AUC = 441.8ng.h/ml.",[Determination of flecainide concentration in blood plasma by HPLC and pharmacokinetic parameters in volunteers]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514579/),1/[h],0.908,145932,DB01195,Flecainide
,2514579,T1/2,"The pharmacokinetic parameters in Chinese volunteers after taking flecainide were: Ka = 0.908h-1, T1/2 = 8.131h, peats time = 3.487h, AUC = 441.8ng.h/ml.",[Determination of flecainide concentration in blood plasma by HPLC and pharmacokinetic parameters in volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514579/),h,8.131,145933,DB01195,Flecainide
,2514579,peats time,"The pharmacokinetic parameters in Chinese volunteers after taking flecainide were: Ka = 0.908h-1, T1/2 = 8.131h, peats time = 3.487h, AUC = 441.8ng.h/ml.",[Determination of flecainide concentration in blood plasma by HPLC and pharmacokinetic parameters in volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514579/),h,3.487,145934,DB01195,Flecainide
,2514579,AUC,"The pharmacokinetic parameters in Chinese volunteers after taking flecainide were: Ka = 0.908h-1, T1/2 = 8.131h, peats time = 3.487h, AUC = 441.8ng.h/ml.",[Determination of flecainide concentration in blood plasma by HPLC and pharmacokinetic parameters in volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514579/),[h·ng] / [ml],441.8,145935,DB01195,Flecainide
,2514579,plasma concentration,The mean plasma concentration of flecainide in cases responded well to this drug was 423.6 +/- 227.4ng/ml.,[Determination of flecainide concentration in blood plasma by HPLC and pharmacokinetic parameters in volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2514579/),[ng] / [ml],423.6,145936,DB01195,Flecainide
,6437721,apparent volume of distribution,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),l,"1300 to 11,000",168376,DB01195,Flecainide
,6437721,elimination half-life,"Its apparent volume of distribution is very large (1300 to 11,000L) and its elimination half-life very long (53 days).",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),d,53,168377,DB01195,Flecainide
,6437721,elimination half-life,"Although it has a short elimination half-life (1 to 3h), 2 major metabolites with antiarrhythmic effects accumulate in the plasma of patients during long term therapy.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,1 to 3,168378,DB01195,Flecainide
,6437721,elimination half-life,"Flecainide, another class Ic antiarrhythmic agent, has an elimination half-life of 14 hours which makes it suitable for twice daily dosing.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,14,168379,DB01195,Flecainide
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,9,168380,DB01195,Flecainide
,6437721,elimination half-lives,The elimination half-lives of lorcainide (9h) and norlorcainide (28h) allow for once or twice daily dosing.,Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,28,168381,DB01195,Flecainide
,6437721,apparent volume of distribution,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),[l] / [kg],5.0 to 6.6,168382,DB01195,Flecainide
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,6 to 12,168383,DB01195,Flecainide
,6437721,elimination half-life,"The apparent volume of distribution of mexiletine is 5.0 to 6.6 L/kg, and the elimination half-life varies from 6 to 12 hours in normal subjects and from 11 to 17 hours in cardiac patients.",Clinical pharmacokinetics of the newer antiarrhythmic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6437721/),h,11 to 17,168384,DB01195,Flecainide
,6326790,cumulative urinary excretion,The cumulative urinary excretion of unchanged flecainide under acidic conditions (134.0 +/- 16.1 mg; mean +/- s.e. mean) was significantly higher than under alkaline conditions (22.3 +/- 7.6 mg; mean +/- s.e. mean) (P less than 0.01).,The influence of urinary pH on flecainide excretion and its serum pharmacokinetics. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326790/),mg,134.0,175896,DB01195,Flecainide
,6326790,cumulative urinary excretion,The cumulative urinary excretion of unchanged flecainide under acidic conditions (134.0 +/- 16.1 mg; mean +/- s.e. mean) was significantly higher than under alkaline conditions (22.3 +/- 7.6 mg; mean +/- s.e. mean) (P less than 0.01).,The influence of urinary pH on flecainide excretion and its serum pharmacokinetics. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6326790/),mg,22.3,175897,DB01195,Flecainide
,2119270,milk to plasma flecainide,"Mean +/- SD milk to plasma flecainide ratios were 3.7 +/- 3.5, 3.2 +/- 2.3, 3.5 +/- 2.1, and 2.6 +/- 0.7 on study days 2, 3, 4, and 5, respectively.",Flecainide excretion in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),,3.7,180007,DB01195,Flecainide
,2119270,milk to plasma flecainide,"Mean +/- SD milk to plasma flecainide ratios were 3.7 +/- 3.5, 3.2 +/- 2.3, 3.5 +/- 2.1, and 2.6 +/- 0.7 on study days 2, 3, 4, and 5, respectively.",Flecainide excretion in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),,3.5,180008,DB01195,Flecainide
,2119270,milk to plasma flecainide,"Mean +/- SD milk to plasma flecainide ratios were 3.7 +/- 3.5, 3.2 +/- 2.3, 3.5 +/- 2.1, and 2.6 +/- 0.7 on study days 2, 3, 4, and 5, respectively.",Flecainide excretion in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),,2.6,180009,DB01195,Flecainide
,2119270,ratios,"Mean +/- SD milk to plasma flecainide ratios were 3.7 +/- 3.5, 3.2 +/- 2.3, 3.5 +/- 2.1, and 2.6 +/- 0.7 on study days 2, 3, 4, and 5, respectively.",Flecainide excretion in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),,3.7,180010,DB01195,Flecainide
,2119270,ratios,"Mean +/- SD milk to plasma flecainide ratios were 3.7 +/- 3.5, 3.2 +/- 2.3, 3.5 +/- 2.1, and 2.6 +/- 0.7 on study days 2, 3, 4, and 5, respectively.",Flecainide excretion in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),,3.2,180011,DB01195,Flecainide
,2119270,ratios,"Mean +/- SD milk to plasma flecainide ratios were 3.7 +/- 3.5, 3.2 +/- 2.3, 3.5 +/- 2.1, and 2.6 +/- 0.7 on study days 2, 3, 4, and 5, respectively.",Flecainide excretion in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),,3.5,180012,DB01195,Flecainide
,2119270,ratios,"Mean +/- SD milk to plasma flecainide ratios were 3.7 +/- 3.5, 3.2 +/- 2.3, 3.5 +/- 2.1, and 2.6 +/- 0.7 on study days 2, 3, 4, and 5, respectively.",Flecainide excretion in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),,2.6,180013,DB01195,Flecainide
,2119270,half-life for elimination,The half-life for elimination of flecainide from milk was 14.7 +/- 3.5 hours and is very similar to the plasma elimination half-life of flecainide in healthy human subjects.,Flecainide excretion in human breast milk. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),h,14.7,180014,DB01195,Flecainide
,2119270,milk to plasma ratios,"The mean milk to plasma ratios for flecainide after the last dose were 2.3 +/- 1.0 and 2.9 +/- 1.1 at 24 and 48 hours after the dose, respectively.",Flecainide excretion in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),,2.3,180015,DB01195,Flecainide
,2119270,milk to plasma ratios,"The mean milk to plasma ratios for flecainide after the last dose were 2.3 +/- 1.0 and 2.9 +/- 1.1 at 24 and 48 hours after the dose, respectively.",Flecainide excretion in human breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),,2.9,180016,DB01195,Flecainide
,2119270,steady-state plasma concentration,"Based on the pharmacokinetics of flecainide in infants, the expected average steady-state plasma concentration of flecainide in a newborn infant consuming all of the milk production of its mother (approximately 700 ml/day) would not be expected to exceed about 62 ng/ml.",Flecainide excretion in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),[ml] / [d],700,180017,DB01195,Flecainide
exceed,2119270,steady-state plasma concentration,"Based on the pharmacokinetics of flecainide in infants, the expected average steady-state plasma concentration of flecainide in a newborn infant consuming all of the milk production of its mother (approximately 700 ml/day) would not be expected to exceed about 62 ng/ml.",Flecainide excretion in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119270/),[ng] / [ml],62,180018,DB01195,Flecainide
,3145942,Peak flecainide acetate concentrations,Measurements and primary results: Peak flecainide acetate concentrations (micrograms/L) were 330 +/- 104 micrograms/L (mean +/- SD) after the single dose and 687 +/- 505 micrograms/L after multiple doses.,Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),[μg] / [l],330,184866,DB01195,Flecainide
,3145942,Peak flecainide acetate concentrations,Measurements and primary results: Peak flecainide acetate concentrations (micrograms/L) were 330 +/- 104 micrograms/L (mean +/- SD) after the single dose and 687 +/- 505 micrograms/L after multiple doses.,Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),[μg] / [l],687,184867,DB01195,Flecainide
,3145942,Time to peak,"Time to peak occurred at 3.3 +/- 2.3 hours and 2.7 +/- 1.2 hours after single and multiple doses, respectively.",Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),h,3.3,184868,DB01195,Flecainide
,3145942,Time to peak,"Time to peak occurred at 3.3 +/- 2.3 hours and 2.7 +/- 1.2 hours after single and multiple doses, respectively.",Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),h,2.7,184869,DB01195,Flecainide
,3145942,apparent volume of distribution,"The apparent volume of distribution was 8.2 +/- 2.9 L/kg and 9.2 +/- 5 L/kg after single and multiple dose studies, respectively.",Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),[l] / [kg],8.2,184870,DB01195,Flecainide
,3145942,apparent volume of distribution,"The apparent volume of distribution was 8.2 +/- 2.9 L/kg and 9.2 +/- 5 L/kg after single and multiple dose studies, respectively.",Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),[l] / [kg],9.2,184871,DB01195,Flecainide
,3145942,Plasma elimination half-life,"Plasma elimination half-life after the single dose (20.4 +/- 9.0 hours) was significantly shorter (P less than .001) than after multiple doses (37.8 +/- 39.7 hours), as was total body clearance: 391 +/- 154 mL/min versus 302 +/- 194 mL/min.",Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),h,20.4,184872,DB01195,Flecainide
,3145942,Plasma elimination half-life,"Plasma elimination half-life after the single dose (20.4 +/- 9.0 hours) was significantly shorter (P less than .001) than after multiple doses (37.8 +/- 39.7 hours), as was total body clearance: 391 +/- 154 mL/min versus 302 +/- 194 mL/min.",Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),h,37.8,184873,DB01195,Flecainide
,3145942,total body clearance,"Plasma elimination half-life after the single dose (20.4 +/- 9.0 hours) was significantly shorter (P less than .001) than after multiple doses (37.8 +/- 39.7 hours), as was total body clearance: 391 +/- 154 mL/min versus 302 +/- 194 mL/min.",Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),[ml] / [min],391,184874,DB01195,Flecainide
,3145942,total body clearance,"Plasma elimination half-life after the single dose (20.4 +/- 9.0 hours) was significantly shorter (P less than .001) than after multiple doses (37.8 +/- 39.7 hours), as was total body clearance: 391 +/- 154 mL/min versus 302 +/- 194 mL/min.",Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145942/),[ml] / [min],302,184875,DB01195,Flecainide
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,90.8,189038,DB01195,Flecainide
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,136,189039,DB01195,Flecainide
,1491037,flow-rate,"After derivatization with the enantiomerically pure reagent (S)-(+)-1-(1-naphthyl)ethyl isocyanate, methocarbamol diastereomers and the (R)-flecainide derivative were separated on a normal-phase silica column with a mobile phase consisting of hexane-isopropanol (95:5, v/v) at a flow-rate of 1.6 ml/min.",High-performance liquid chromatographic analysis of methocarbamol enantiomers in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491037/),[ml] / [min],1.6,191967,DB01195,Flecainide
,1491037,signal-to-noise ratio,"The lowest quantifiable concentration was 0.5 microgram/ml for each enantiomer (coefficients of variation of 9.8 and 8.8% for (S)- and (R)-methocarbamol, respectively), while the limit of detection (signal-to-noise ratio 3:1) was approximately 10 ng/ml.",High-performance liquid chromatographic analysis of methocarbamol enantiomers in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491037/),[ng] / [ml],3,191968,DB01195,Flecainide
,1491037,signal-to-noise ratio,"The lowest quantifiable concentration was 0.5 microgram/ml for each enantiomer (coefficients of variation of 9.8 and 8.8% for (S)- and (R)-methocarbamol, respectively), while the limit of detection (signal-to-noise ratio 3:1) was approximately 10 ng/ml.",High-performance liquid chromatographic analysis of methocarbamol enantiomers in biological fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491037/),[ng] / [ml],10,191969,DB01195,Flecainide
,2111245,systemic clearance,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),[ml] / [kg·min],9.1,192659,DB01195,Flecainide
,2111245,systemic clearance,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),[ml] / [kg·min],7.6,192660,DB01195,Flecainide
,2111245,elimination half-life,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),h,9.6,192661,DB01195,Flecainide
,2111245,elimination half-life,"Quinine administration did not change the apparent volume of distribution or the renal clearance of flecainide, but it significantly reduced its systemic clearance (9.1 vs 7.6 ml.kg-1.min-1), thus increasing the elimination half-life (9.6 vs 11.5 h).",Altered flecainide disposition in healthy volunteers taking quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2111245/),h,11.5,192662,DB01195,Flecainide
,2110973,flow rate,The diastereomeric derivatives of flecainide and IS were chromatographed on a C18 reversed-phase column with a mobile phase consisting of acetonitrile: water:triethylamine (45:55:0.2) at a flow rate of 1 mL/min.,High-performance liquid chromatographic determination of the enantiomers of flecainide in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2110973/),[ml] / [min],1,197507,DB01195,Flecainide
,4074602,elimination half-life,However the plasma elimination of flecainide was found to be inversely proportional to urinary pH and the volunteers' mean elimination half-life ranged between 10.7 +/- 3.2 h (s.d.) at the extreme acid pH and 17.6 +/- 6.3 h at the extreme alkali pH.,Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074602/),h,10.7,205483,DB01195,Flecainide
,4074602,elimination half-life,However the plasma elimination of flecainide was found to be inversely proportional to urinary pH and the volunteers' mean elimination half-life ranged between 10.7 +/- 3.2 h (s.d.) at the extreme acid pH and 17.6 +/- 6.3 h at the extreme alkali pH.,Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4074602/),h,17.6,205484,DB01195,Flecainide
,1782979,Ae,"At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h).",Elimination of flecainide as a function of urinary flow rate and pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),mg,5.8,208451,DB01195,Flecainide
,1782979,Ae,"At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h).",Elimination of flecainide as a function of urinary flow rate and pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),mg,2.6,208452,DB01195,Flecainide
,1782979,CLR,"At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h).",Elimination of flecainide as a function of urinary flow rate and pH. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[ml] / [min],73,208453,DB01195,Flecainide
,1782979,CLR,"At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h).",Elimination of flecainide as a function of urinary flow rate and pH. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[ml] / [min],33,208454,DB01195,Flecainide
,1782979,half-life,"At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h).",Elimination of flecainide as a function of urinary flow rate and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),h,15.7,208455,DB01195,Flecainide
,1782979,half-life,"At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h).",Elimination of flecainide as a function of urinary flow rate and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),h,16.0,208456,DB01195,Flecainide
,1782979,AUC,"At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h).",Elimination of flecainide as a function of urinary flow rate and pH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),h,16.0,208457,DB01195,Flecainide
,1782979,AUC,"At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h).",Elimination of flecainide as a function of urinary flow rate and pH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[h·ng] / [ml],1480,208458,DB01195,Flecainide
,1782979,AUC,"At alkaline pH Ae (5.8 vs 2.6 mg) and CLR (73 vs 33 ml.min-1) were significantly affected by fluid load (high vs low), whereas half-life and AUC were not different (15.7 vs 16.0 h, 1480 vs 1540 ng.ml-1.h).",Elimination of flecainide as a function of urinary flow rate and pH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[h·ng] / [ml],1540,208459,DB01195,Flecainide
,1782979,half-life,For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml.min-1; AUC 976 vs 1480 ng.ml-1.h.,Elimination of flecainide as a function of urinary flow rate and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),h,10.0,208460,DB01195,Flecainide
,1782979,half-life,For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml.min-1; AUC 976 vs 1480 ng.ml-1.h.,Elimination of flecainide as a function of urinary flow rate and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),h,15.7,208461,DB01195,Flecainide
,1782979,Ae,For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml.min-1; AUC 976 vs 1480 ng.ml-1.h.,Elimination of flecainide as a function of urinary flow rate and pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),mg,15.9,208462,DB01195,Flecainide
,1782979,Ae,For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml.min-1; AUC 976 vs 1480 ng.ml-1.h.,Elimination of flecainide as a function of urinary flow rate and pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),mg,5.8,208463,DB01195,Flecainide
,1782979,CLR,For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml.min-1; AUC 976 vs 1480 ng.ml-1.h.,Elimination of flecainide as a function of urinary flow rate and pH. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[ml] / [min],288,208464,DB01195,Flecainide
,1782979,CLR,For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml.min-1; AUC 976 vs 1480 ng.ml-1.h.,Elimination of flecainide as a function of urinary flow rate and pH. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[ml] / [min],73,208465,DB01195,Flecainide
,1782979,AUC,For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml.min-1; AUC 976 vs 1480 ng.ml-1.h.,Elimination of flecainide as a function of urinary flow rate and pH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[h·ng] / [ml],976,208466,DB01195,Flecainide
,1782979,AUC,For a high fluid load the values at acidic vs alkaline pH were half-life 10.0 vs 15.7 h; Ae 15.9 vs 5.8 mg; CLR 288 vs 73 ml.min-1; AUC 976 vs 1480 ng.ml-1.h.,Elimination of flecainide as a function of urinary flow rate and pH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[h·ng] / [ml],1480,208467,DB01195,Flecainide
,1782979,half-life,For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml.min-1; AUC 1045 vs 1540 ng.,Elimination of flecainide as a function of urinary flow rate and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),h,10.1,208468,DB01195,Flecainide
,1782979,half-life,For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml.min-1; AUC 1045 vs 1540 ng.,Elimination of flecainide as a function of urinary flow rate and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),h,16.0,208469,DB01195,Flecainide
,1782979,Ae,For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml.min-1; AUC 1045 vs 1540 ng.,Elimination of flecainide as a function of urinary flow rate and pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),mg,15.9,208470,DB01195,Flecainide
,1782979,Ae,For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml.min-1; AUC 1045 vs 1540 ng.,Elimination of flecainide as a function of urinary flow rate and pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),mg,2.6,208471,DB01195,Flecainide
,1782979,CLR,For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml.min-1; AUC 1045 vs 1540 ng.,Elimination of flecainide as a function of urinary flow rate and pH. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[ml] / [min],267,208472,DB01195,Flecainide
,1782979,CLR,For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml.min-1; AUC 1045 vs 1540 ng.,Elimination of flecainide as a function of urinary flow rate and pH. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),[ml] / [min],33,208473,DB01195,Flecainide
,1782979,AUC,For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml.min-1; AUC 1045 vs 1540 ng.,Elimination of flecainide as a function of urinary flow rate and pH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),ng,1045,208474,DB01195,Flecainide
,1782979,AUC,For a low fluid load the corresponding values at acidic vs alkaline pH were half-life 10.1 vs 16.0 h; Ae 15.9 vs 2.6 mg; CLR 267 vs 33 ml.min-1; AUC 1045 vs 1540 ng.,Elimination of flecainide as a function of urinary flow rate and pH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782979/),ng,1540,208475,DB01195,Flecainide
,3132493,systemic,"Its systemic and hemofiltrate clearances, measured in a patient under continuous hemofiltration, were 402 and 19.7 ml/min respectively.",Hemofiltration clearance of flecainide in a patient with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132493/),[ml] / [min],402,212707,DB01195,Flecainide
,3132493,hemofiltrate clearances,"Its systemic and hemofiltrate clearances, measured in a patient under continuous hemofiltration, were 402 and 19.7 ml/min respectively.",Hemofiltration clearance of flecainide in a patient with acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132493/),[ml] / [min],19.7,212708,DB01195,Flecainide
less,3132493,clearance ratio,The clearance ratio of less than 5% makes the contribution of hemofiltration to the elimination of flecainide clinically negligible.,Hemofiltration clearance of flecainide in a patient with acute renal failure. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3132493/),%,5,212709,DB01195,Flecainide
,2500470,serum trough levels,Doses of flecainide ranged from 59 to 225 mg/m2 body surface area per day (mean 141) in divided doses every 8 to 12 h and serum trough levels ranged from 0.10 to 0.99 micrograms/ml (mean 0.36).,Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500470/),[μg] / [ml],0.36,220478,DB01195,Flecainide
,2500470,plasma elimination half-life (t 1/2),Young infants (less than 1 year of age) had a mean plasma elimination half-life (t 1/2) approximating that (11 to 12 h) found in older children and healthy adults; children aged 1 to 12 years had a shorter mean t 1/2 of 8 h.,Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500470/),h,11 to 12,220479,DB01195,Flecainide
,2500470,t 1/2,Young infants (less than 1 year of age) had a mean plasma elimination half-life (t 1/2) approximating that (11 to 12 h) found in older children and healthy adults; children aged 1 to 12 years had a shorter mean t 1/2 of 8 h.,Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500470/),h,8,220480,DB01195,Flecainide
,1906003,half-lives,The half-lives of R- and S-flecainide in PMs (R 19.3 h; S 16.1 h) were approximately twice those observed in EMs (R 8.8 h; S 9.1 h).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),h,19.3,221014,DB01195,Flecainide
,1906003,half-lives,The half-lives of R- and S-flecainide in PMs (R 19.3 h; S 16.1 h) were approximately twice those observed in EMs (R 8.8 h; S 9.1 h).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),h,16.1,221015,DB01195,Flecainide
,1906003,half-lives,The half-lives of R- and S-flecainide in PMs (R 19.3 h; S 16.1 h) were approximately twice those observed in EMs (R 8.8 h; S 9.1 h).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),h,8.8,221016,DB01195,Flecainide
,1906003,half-lives,The half-lives of R- and S-flecainide in PMs (R 19.3 h; S 16.1 h) were approximately twice those observed in EMs (R 8.8 h; S 9.1 h).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),h,9.1,221017,DB01195,Flecainide
,1906003,apparent oral clearances,The apparent oral clearances of R- and S-flecainide were lower in PMs (R 313 ml.min-1; S 379 ml.min-1) than in EMs (R 783 ml.min-1; S 828 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],313,221018,DB01195,Flecainide
,1906003,apparent oral clearances,The apparent oral clearances of R- and S-flecainide were lower in PMs (R 313 ml.min-1; S 379 ml.min-1) than in EMs (R 783 ml.min-1; S 828 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],379,221019,DB01195,Flecainide
,1906003,apparent oral clearances,The apparent oral clearances of R- and S-flecainide were lower in PMs (R 313 ml.min-1; S 379 ml.min-1) than in EMs (R 783 ml.min-1; S 828 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],783,221020,DB01195,Flecainide
,1906003,apparent oral clearances,The apparent oral clearances of R- and S-flecainide were lower in PMs (R 313 ml.min-1; S 379 ml.min-1) than in EMs (R 783 ml.min-1; S 828 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],828,221021,DB01195,Flecainide
,1906003,nonrenal clearance,The nonrenal clearance of both enantiomers was significantly lower in poor (R 123 ml.min-1; S 201 ml.min-1) relative to extensive metabolisers (R 533 ml.min-1; S 586 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],123,221022,DB01195,Flecainide
,1906003,nonrenal clearance,The nonrenal clearance of both enantiomers was significantly lower in poor (R 123 ml.min-1; S 201 ml.min-1) relative to extensive metabolisers (R 533 ml.min-1; S 586 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],201,221023,DB01195,Flecainide
,1906003,nonrenal clearance,The nonrenal clearance of both enantiomers was significantly lower in poor (R 123 ml.min-1; S 201 ml.min-1) relative to extensive metabolisers (R 533 ml.min-1; S 586 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],533,221024,DB01195,Flecainide
,1906003,nonrenal clearance,The nonrenal clearance of both enantiomers was significantly lower in poor (R 123 ml.min-1; S 201 ml.min-1) relative to extensive metabolisers (R 533 ml.min-1; S 586 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],586,221025,DB01195,Flecainide
,1906003,partial clearance,The partial clearance to the two major metabolites meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) was significantly lower in poor (62 ml.min-1) than extensive (267 ml.min-1) metabolisers.,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],62,221026,DB01195,Flecainide
,1906003,partial clearance,The partial clearance to the two major metabolites meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) was significantly lower in poor (62 ml.min-1) than extensive (267 ml.min-1) metabolisers.,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],267,221027,DB01195,Flecainide
,12189358,relative bioavailability,"Compared with the immediate-release formulation, the relative bioavailability of the controlled-release formulation at steady state was 0.85 +/- 0.17 and 0.89 +/- 0.17 for the 100-mg/day and 200-mg/day doses, respectively.",Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189358/),,0.85,225222,DB01195,Flecainide
,12189358,relative bioavailability,"Compared with the immediate-release formulation, the relative bioavailability of the controlled-release formulation at steady state was 0.85 +/- 0.17 and 0.89 +/- 0.17 for the 100-mg/day and 200-mg/day doses, respectively.",Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189358/),,0.89,225223,DB01195,Flecainide
,1576047,clearance,"3. In five extensive metabolizer patients, quinidine significantly reduced the clearance of R-(-)-flecainide, from 395 +/- 121 (s.d.) to 335 +/- 88 ml min-1.",Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576047/),[ml] / [min],395,235218,DB01195,Flecainide
,1576047,clearance,"3. In five extensive metabolizer patients, quinidine significantly reduced the clearance of R-(-)-flecainide, from 395 +/- 121 (s.d.) to 335 +/- 88 ml min-1.",Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576047/),[ml] / [min],335,235219,DB01195,Flecainide
,19566113,absolute bioavailability,"The absolute bioavailability is 20-25%, and administration of cinacalcet with low- or high-fat meals increases exposure (area under the plasma concentration-time curve from time zero to infinity [AUC(infinity)]) 1.5- to 1.8-fold.",Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566113/),%,20-25,235608,DB01195,Flecainide
,19566113,terminal elimination half-life,"The terminal elimination half-life is 30-40 hours, and steady-state concentrations are achieved within 7 days.",Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566113/),h,30-40,235609,DB01195,Flecainide
,7019711,effective dose,"The mean effective dose was 189 mg per 12 hours, and the effective plasma concentration before administration of a dose averaged 635 ng per milliliter.",Oral flecainide acetate for the treatment of ventricular arrhythmias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7019711/),mg,189,248222,DB01195,Flecainide
,7019711,effective plasma concentration,"The mean effective dose was 189 mg per 12 hours, and the effective plasma concentration before administration of a dose averaged 635 ng per milliliter.",Oral flecainide acetate for the treatment of ventricular arrhythmias. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7019711/),[ng] / [milliliter],635,248223,DB01195,Flecainide
,7019711,elimination half-life,The elimination half-life was long - 18.8 +/- 3.8 hours.,Oral flecainide acetate for the treatment of ventricular arrhythmias. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7019711/),h,18.8,248224,DB01195,Flecainide
,2498026,AUC,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[h·ng] / [ml],1462,248880,DB01195,Flecainide
,2498026,AUC,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[h·ng] / [ml],860,248881,DB01195,Flecainide
,2498026,elimination half-life,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),h,11.8,248882,DB01195,Flecainide
,2498026,elimination half-life,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),h,6.8,248883,DB01195,Flecainide
,2498026,amount excreted,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),mg,26.7,248884,DB01195,Flecainide
,2498026,amount excreted,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),mg,15.4,248885,DB01195,Flecainide
,2498026,Oral clearance,Oral clearance of flecainide was reduced (p less than 0.019) in PMs (600 +/- 139 versus 1041 +/- 307 ml/min in EMs).,The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],600,248886,DB01195,Flecainide
,2498026,Oral clearance,Oral clearance of flecainide was reduced (p less than 0.019) in PMs (600 +/- 139 versus 1041 +/- 307 ml/min in EMs).,The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],1041,248887,DB01195,Flecainide
,2498026,renal clearance,"The renal clearance was similar (p greater than 0.05) in PMs (308 +/- 70 ml/min) and EMs (315 +/- 69 ml/min) and, consequently, PMs had a lower (p less than 0.008) metabolic clearance of flecainide (292 +/- 136 versus 726 +/- 240 ml/min in EMs).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],308,248888,DB01195,Flecainide
,2498026,renal clearance,"The renal clearance was similar (p greater than 0.05) in PMs (308 +/- 70 ml/min) and EMs (315 +/- 69 ml/min) and, consequently, PMs had a lower (p less than 0.008) metabolic clearance of flecainide (292 +/- 136 versus 726 +/- 240 ml/min in EMs).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],315,248889,DB01195,Flecainide
,2498026,metabolic clearance,"The renal clearance was similar (p greater than 0.05) in PMs (308 +/- 70 ml/min) and EMs (315 +/- 69 ml/min) and, consequently, PMs had a lower (p less than 0.008) metabolic clearance of flecainide (292 +/- 136 versus 726 +/- 240 ml/min in EMs).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],292,248890,DB01195,Flecainide
,2498026,metabolic clearance,"The renal clearance was similar (p greater than 0.05) in PMs (308 +/- 70 ml/min) and EMs (315 +/- 69 ml/min) and, consequently, PMs had a lower (p less than 0.008) metabolic clearance of flecainide (292 +/- 136 versus 726 +/- 240 ml/min in EMs).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],726,248891,DB01195,Flecainide
,3094570,Absolute bioavailability,Absolute bioavailability of oral flecainide averaged 70% (range 60-86%).,"Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),%,70,254852,DB01195,Flecainide
,3094570,apparent volume of distribution,The apparent volume of distribution of 5.5 +/- 0.3 l kg-1 indicates wide distribution of flecainide in tissues.,"Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[l] / [kg],5.5,254853,DB01195,Flecainide
,3094570,elimination half-lives,"Estimated elimination half-lives from plasma data averaged 9.3 to 12.4 h (single oral dose studies), 11.8 h (single i.v. dose), and 11.5 h (multiple oral dose).","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),h,9.3 to 12.4,254854,DB01195,Flecainide
,3094570,elimination half-lives,"Estimated elimination half-lives from plasma data averaged 9.3 to 12.4 h (single oral dose studies), 11.8 h (single i.v. dose), and 11.5 h (multiple oral dose).","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),h,11.8,254855,DB01195,Flecainide
,3094570,elimination half-lives,"Estimated elimination half-lives from plasma data averaged 9.3 to 12.4 h (single oral dose studies), 11.8 h (single i.v. dose), and 11.5 h (multiple oral dose).","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),h,11.5,254856,DB01195,Flecainide
,3094570,CLNR,Following i.v. dosing CLNR and CLR averaged respectively 3.24 +/- 0.80 and 2.38 +/- 0.49 ml min-1 kg-1.,"Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[ml] / [kg·min],3.24,254857,DB01195,Flecainide
,3094570,CLR,Following i.v. dosing CLNR and CLR averaged respectively 3.24 +/- 0.80 and 2.38 +/- 0.49 ml min-1 kg-1.,"Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[ml] / [kg·min],2.38,254858,DB01195,Flecainide
,3094570,trough,"After 200 mg twice daily oral treatment steady state was reached within 3-4 days with trough and peak plasma levels on day 8 of 457 and 662 ng ml-1, which are well within the therapeutic range.","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[ng] / [ml],457,254859,DB01195,Flecainide
,3094570,peak plasma levels,"After 200 mg twice daily oral treatment steady state was reached within 3-4 days with trough and peak plasma levels on day 8 of 457 and 662 ng ml-1, which are well within the therapeutic range.","Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3094570/),[ng] / [ml],662,254860,DB01195,Flecainide
